Lovastatin, an inhibitor of the rate-limiting cholesterol synthesis enzyme 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, downregulates PI3K, AKT, and mammalian target of rapamycin (mTOR) in colorectal cancer cells via a phosphatase and tensin homologue (PTEN)- and bone morphogenetic protein (BMP)-dependent manner [84]. This evidence concerns the gene MTOR and colorectal cancer.